AI In Cancer Diagnostics Market Growth, Size, Trends Analysis - By Component, By Cancer Type, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
Description
AI In Cancer Diagnostics Market Introduction and Overview
According to SPER market research, ‘Global AI In Cancer Diagnostics Market Size- By Component, By Cancer Type, By End-User – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global AI In Cancer Diagnostics Market is predicted to reach 2413.59 million by 2034 with a CAGR of 24.39%.
Artificial intelligence (AI) in the field of cancer diagnostics pertains to the application of sophisticated computational algorithms and machine learning methodologies to aid in the detection, diagnosis, and treatment planning for cancer. AI algorithms are capable of recognizing patterns in medical images, allowing for quicker and more precise identification of diseases such as cancer compared to traditional techniques. Additionally, it supports pathologists in the analysis of tissue samples, contributing to a more accurate identification of diseases like cancer.
Restraints: AI in cancer diagnostics necessitates the management of substantial datasets and an understanding of the applications and potential limitations of deep learning technologies. Therefore, the deficiency in knowledge and training regarding AI systems represents the most significant obstacle that could restrict market growth in the upcoming years. Furthermore, the implementation of AI might also infringe on privacy due to possible access to sensitive personal information such as genomic sequences, which could further hinder market progress.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered
By Component, By Cancer Type, By End-User
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered
EarlySign, Cancer Center.ai, Microsoft, FLATIRON HEALTH, PathAI, Inc, Therapixel, Tempus AI, Inc, Paige AI Inc, Kheiron Medical Technologies Limited, SkinVision.
Global AI In Cancer Diagnostics Market Segmentation:
By Component: Based on the Component, Global AI In Cancer Diagnostics Market is segmented as; Software Solutions, Hardware, Services.
By Cancer Type: Based on the Cancer Type, Global AI In Cancer Diagnostics Market is segmented as; Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others.
By End User: Based on the End User, Global AI In Cancer Diagnostics Market is segmented as; Hospital, Surgical Centers and Medical Institutes, Others.
By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
According to SPER market research, ‘Global AI In Cancer Diagnostics Market Size- By Component, By Cancer Type, By End-User – Regional Outlook, Competitive Strategies and Segment Forecast to 2034’ state that the Global AI In Cancer Diagnostics Market is predicted to reach 2413.59 million by 2034 with a CAGR of 24.39%.
Artificial intelligence (AI) in the field of cancer diagnostics pertains to the application of sophisticated computational algorithms and machine learning methodologies to aid in the detection, diagnosis, and treatment planning for cancer. AI algorithms are capable of recognizing patterns in medical images, allowing for quicker and more precise identification of diseases such as cancer compared to traditional techniques. Additionally, it supports pathologists in the analysis of tissue samples, contributing to a more accurate identification of diseases like cancer.
Restraints: AI in cancer diagnostics necessitates the management of substantial datasets and an understanding of the applications and potential limitations of deep learning technologies. Therefore, the deficiency in knowledge and training regarding AI systems represents the most significant obstacle that could restrict market growth in the upcoming years. Furthermore, the implementation of AI might also infringe on privacy due to possible access to sensitive personal information such as genomic sequences, which could further hinder market progress.
Scope of the report:
Report Metric Details
Market size available for years 2021-2034
Base year considered 2024
Forecast period 2025-2034
Segments covered
By Component, By Cancer Type, By End-User
Regions covered
North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa
Companies Covered
EarlySign, Cancer Center.ai, Microsoft, FLATIRON HEALTH, PathAI, Inc, Therapixel, Tempus AI, Inc, Paige AI Inc, Kheiron Medical Technologies Limited, SkinVision.
Global AI In Cancer Diagnostics Market Segmentation:
By Component: Based on the Component, Global AI In Cancer Diagnostics Market is segmented as; Software Solutions, Hardware, Services.
By Cancer Type: Based on the Cancer Type, Global AI In Cancer Diagnostics Market is segmented as; Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others.
By End User: Based on the End User, Global AI In Cancer Diagnostics Market is segmented as; Hospital, Surgical Centers and Medical Institutes, Others.
By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.
Table of Contents
250 Pages
- 1. Introduction
- 1.1. Scope of the report
- 1.2. Market segment analysis
- 2. Research Methodology
- 2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPERs internal database
- 2.1.4. Premium insight from KOLs
- 2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
- 2.3. Data triangulation
- 3. Executive Summary
- 4. Market Dynamics
- 4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
- 5. Market variable and outlook
- 5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
- 5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
- 5.3. PORTERs Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
- 5.4. Heat Map Analysis
- 6. Competitive Landscape
- 6.1. Global AI In Cancer Diagnostics Market Manufacturing Base Distribution, Sales Area, Product Type
- 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global AI In Cancer Diagnostics Market
- 7. Global AI In Cancer Diagnostics Market, By Component (USD Million) 2021-2034
- 7.1. Software Solutions
- 7.2. Hardware
- 7.3. Services
- 8. Global AI In Cancer Diagnostics Market, By Cancer Type (USD Million) 2021-2034
- 8.1. Breast Cancer
- 8.2. Lung Cancer
- 8.3. Prostate Cancer
- 8.4. Colorectal Cancer
- 8.5. Brain Tumor
- 8.6. Others
- 9. Global AI In Cancer Diagnostics Market, By End-User (USD Million) 2021-2034
- 9.1. Hospital
- 9.2. Surgical Centers and Medical Institutes
- 9.3. Others
- 10. Global AI In Cancer Diagnostics Market, (USD Million) 2021-2034
- 10.1. Global AI In Cancer Diagnostics Market Size and Market Share
- 11. Global AI In Cancer Diagnostics Market, By Region, (USD Million) 2021-2034
- 11.1. Asia-Pacific
- 11.1.1. Australia
- 11.1.2. China
- 11.1.3. India
- 11.1.4. Japan
- 11.1.5. South Korea
- 11.1.6. Rest of Asia-Pacific
- 11.2. Europe
- 11.2.1. France
- 11.2.2. Germany
- 11.2.3. Italy
- 11.2.4. Spain
- 11.2.5. United Kingdom
- 11.2.6. Rest of Europe
- 11.3. Middle East and Africa
- 11.3.1. Kingdom of Saudi Arabia
- 11.3.2. United Arab Emirates
- 11.3.3. Qatar
- 11.3.4. South Africa
- 11.3.5. Egypt
- 11.3.6. Morocco
- 11.3.7. Nigeria
- 11.3.8. Rest of Middle-East and Africa
- 11.4. North America
- 11.4.1. Canada
- 11.4.2. Mexico
- 11.4.3. United States
- 11.5. Latin America
- 11.5.1. Argentina
- 11.5.2. Brazil
- 11.5.3. Rest of Latin America
- 12. Company Profile
- 12.1. EarlySign
- 12.1.1. Company details
- 12.1.2. Financial outlook
- 12.1.3. Product summary
- 12.1.4. Recent developments
- 12.2. Cancer Center.ai
- 12.2.1. Company details
- 12.2.2. Financial outlook
- 12.2.3. Product summary
- 12.2.4. Recent developments
- 12.3. Microsoft
- 12.3.1. Company details
- 12.3.2. Financial outlook
- 12.3.3. Product summary
- 12.3.4. Recent developments
- 12.4. FLATIRON HEALTH
- 12.4.1. Company details
- 12.4.2. Financial outlook
- 12.4.3. Product summary
- 12.4.4. Recent developments
- 12.5. PathAI, Inc
- 12.5.1. Company details
- 12.5.2. Financial outlook
- 12.5.3. Product summary
- 12.5.4. Recent developments
- 12.6. Therapixel
- 12.6.1. Company details
- 12.6.2. Financial outlook
- 12.6.3. Product summary
- 12.6.4. Recent developments
- 12.7. Tempus AI, Inc
- 12.7.1. Company details
- 12.7.2. Financial outlook
- 12.7.3. Product summary
- 12.7.4. Recent developments
- 12.8. Paige AI Inc
- 12.8.1. Company details
- 12.8.2. Financial outlook
- 12.8.3. Product summary
- 12.8.4. Recent developments
- 12.9. Kheiron Medical Technologies Limited
- 12.9.1. Company details
- 12.9.2. Financial outlook
- 12.9.3. Product summary
- 12.9.4. Recent developments
- 12.10. SkinVision
- 12.10.1. Company details
- 12.10.2. Financial outlook
- 12.10.3. Product summary
- 12.10.4. Recent developments
- 12.11. Others
- 13. Conclusion
- 14. List of Abbreviations
- 15. Reference Links
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.